Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 0.49 |
| ▸ | PDGFRA known ✓ | P16234 | 2/20 | 0.49 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.46 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.46 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.41 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | CFTR | P13569 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1496359 | 0.98 | CYP1A2 (0.52) | CYP1A2PDGFRBPDGFRAKMT2AKDM1A | |
| Hydrochloric Acid SCHEMBL5833175 | 0.92 | ALDH1A1 (0.45) | CYP1A2PDGFRBPDGFRAKMT2AKDM1A | |
| SCHEMBL28151161 | 0.83 | CYP1A2 (0.48) | CYP1A2PDGFRBPDGFRAKDM1AMAOA | |
| SCHEMBL3396692 | 0.82 | CYP1A2 (0.55) | CYP1A2PDGFRBPDGFRAKDM1AMAOA | |
| Hydrochloric Acid SCHEMBL5834538 | 0.82 | MGAM (0.41) | CYP1A2KMT2AMGAMRAB9ACFTR | |
| Hydrochloric Acid SCHEMBL29899399 | 0.81 | CYP1A2 (0.50) | CYP1A2PDGFRBPDGFRAKDM1AMAOA | |
| Hydrochloric Acid SCHEMBL9433989 | 0.81 | ALDH1A1 (0.51) | CYP1A2PDGFRBPDGFRAKMT2AKDM1A | |
| Hydrochloric Acid SCHEMBL507381 | 0.81 | CYP1A2 (0.50) | CYP1A2PDGFRBPDGFRAKDM1AMAOA | |
| Hydrochloric Acid SCHEMBL243246 | 0.81 | CYP1A2 (0.50) | CYP1A2PDGFRBPDGFRAKDM1AMAOA | |
| SCHEMBL9118575 | 0.80 | CYP1A2 (0.46) | CYP1A2PDGFRBPDGFRAKDM1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9670181-B2 | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) | ALLERGAN, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| EP-2675791-B1 | SUBSTITUTED 6,7-DIALKOXY-3-ISOQUINOLINOL DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE10A) | ALLERGAN INC (US) | 2016-02-17 | — | — | EP | disclosed |
| US-20140309253-A1 | SUBSTITUTED 6,7-DIALKOXY-3-ISOQUINOLINOL DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE 10A) | ALLERGAN, INC. | 2014-10-16 | — | — | US | disclosed |
| US-8772316-B2 | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE10A) | ALLERGAN, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| EP-2675791-A1 | SUBSTITUTED 6,7-DIALKOXY-3-ISOQUINOLINOL DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE10A) | Allergan, Inc. (US) | 2013-12-25 | — | — | EP | disclosed |
| CN-103476757-A | Substituted 6, 7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10(PDE10A) | ALLERGAN INC | 2013-12-25 | — | — | CN | disclosed |
| EP-2066627-B1 | NOVEL MINOR GROOVE BINDERS | UNIV STRATHCLYDE (GB) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012112946-A1 | SUBSTITUTED 6,7-DIALKOXY-3-ISOQUINOLINOL DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE10A) | ALLERGAN, INC. (US) | 2012-08-23 | — | — | WO | disclosed |
| US-20120214837-A1 | SUBSTITUTED 6,7-DIALKOXY-3-ISOQUINOLINOL DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE10A) | EXONHIT THERAPEUTICS SA (FR) | 2012-08-23 | — | — | US | disclosed |
| US-8012967-B2 | Minor groove binders | UNIVERSITY OF STRATHCLYDE (GB) | 2011-09-06 | — | — | US | disclosed |
| WO-2001053274-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2001-07-26 | — | — | WO | disclosed |
| US-5639885-A | Redox amino acids and peptides containing them | UNIVERSITY OF FLORIDA (US) | 1997-06-17 | — | — | US | disclosed |
| US-5283245-A | Antiinflammatory agent, antiallergens | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-02-01 | — | — | US | disclosed |
| EP-0293071-B1 | REDOX AMINO ACIDS AND PEPTIDES CONTAINING THEM | UNIVERSITY OF FLORIDA (US) | 1993-09-01 | — | — | EP | disclosed |
| US-5089495-A | Lipoxygenase inhibitors | IMPERIAL CHEMICAL INDUSTRIES PLC (FR) | 1992-02-18 | — | — | US | disclosed |
| US-5079366-A | To derivatize pharmaceutical peptides for transport across the blood/brain barrier | UNIVERSITY OF FLORIDA (US) | 1992-01-07 | — | — | US | disclosed |
| EP-0381375-A1 | Heterocyclic derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-08-08 | — | — | EP | disclosed |
| US-4888427-A | DIHYDROPYRIDINE-PYRIDINIUM SALT REDOX SYSTEM | UNIVERSITY OF FLORIDA (US) | 1989-12-19 | — | — | US | disclosed |
| EP-0293071-A1 | Redox amino acids and peptides containing them | UNIVERSITY OF FLORIDA (US) | 1988-11-30 | — | — | EP | disclosed |
| US-4379154-A | Thiocarboxamide derivatives and their use as pharmaceuticals | RHONE-POULENC SANTE (FR) | 1983-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309253-A1 | SUBSTITUTED 6,7-DIALKOXY-3-ISOQUINOLINOL DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE 10A) | PDE10A, PDE6A, PDE9A | PDGFRB 1320/4885PDGFRA 1047/4885MAOA 268/4885 |
| US-20120214837-A1 | SUBSTITUTED 6,7-DIALKOXY-3-ISOQUINOLINOL DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE10A) | PDE10A, PDE6A, PDE9A | PDGFRB 1349/4885PDGFRA 1031/4885MAOA 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.